ArticleLeukemia2018
Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS.
Abstract read
In one paragraph
Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- U2af1Leukemia · 2026Article
- Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.Leukemia · 2026Article
- Inhibiting ferroptosis enhances ex vivo expansion of human haematopoietic stem cells.Nature cell biology · 2025Article
- Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1-Mutated Acute Myeloid Leukemia.Cancer medicine · 2025Article
- UNISOM: Unified Somatic Calling and Machine Learning-based Classification Enhance the Discovery of CHIP.Genomics, proteomics & bioinformatics · 2025Article
- Article
- Interpreting variants in genes affected by clonal hematopoiesis in population data.Human genetics · 2024Review
- Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.Cancer medicine · 2024Article
- European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.Leukemia · 2023Review
- Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.Haematologica · 2023Article
- Epigenetic regulation by ASXL1 in myeloid malignancies.International journal of hematology · 2023Review
- A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data sets.Blood · 2023Article
- The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease's phenotype.Frontiers in oncology · 2023Article
- Role of ASXL1 in hematopoiesis and myeloid diseases.Experimental hematology · 2022Review
- ASXL1/2 mutations and myeloid malignancies.Journal of hematology & oncology · 2022Review
- Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays.Nature communications · 2022Article
- Analysis of genetic variants in myeloproliferative neoplasms using a 22-gene next-generation sequencing panel.BMC medical genomics · 2022Article
- Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis.International journal of hematology · 2021Article
- Improved Variant Detection in Clinical Myeloid NGS Testing by Supplementing a Commercial Myeloid NGS Assay with Custom or Extended Data Filtering and Accessory Fragment Analysis.Molecular diagnosis & therapy · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Michael O AlbertiDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-4269-4701
Sridhar Nonavinkere SrivatsanDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Jin ShaoDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Samantha N McNultyDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Gue Su ChangDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Christopher A MillerDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-4266-6700
Jennifer B DunlapDepartment of Pathology, Oregon Health & Science University, Portland, OR, USA.
Fei YangDepartment of Pathology, Oregon Health & Science University, Portland, OR, USA.
Richard D PressDepartment of Pathology, Oregon Health & Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0002-2103-5144
Qingsong GaoDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Li DingDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-1517-2975
Jonathan W HeuselDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Eric J DuncavageDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Matthew J WalterDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA. mjwalter@wustl.edu.ORCID http://orcid.org/0000-0002-7753-1091
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MSpecimen Acquistition and Expression ProfilingP01CA101937 · NCI · WASHINGTON UNIVERSITY · PI LEY, TIMOTHY J. · 2003 to 2023
$58.8MTargeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI TODD A FEHNIGER · 2013 to 2026
$31.6MCOMPREHENSIVE INFORMATIC ANALYSES OF AML GENOMES AND EPIGENOMESR50CA211782 · NCI · WASHINGTON UNIVERSITY · PI Christopher A Miller · 2017 to 2026
$1.5MNCI NIH HHS P01 CA101937NCI NIH HHS P30 CA091842NCI NIH HHS P50 CA171963NCI NIH HHS R50 CA211782
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene DuplicationMutationArtifactsBiomarkers, TumorDiagnosis, DifferentialHematologic NeoplasmsHigh-Throughput Nucleotide SequencingHumansMolecular Diagnostic TechniquesMyeloproliferative DisordersPrognosisRepressor ProteinsASXL1 protein, humanBiomarkers, TumorRepressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.